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Abstract
Catechol-O-methyl transferase (COMT) plays a key role in the degradation of brain dopamine (DA). Specifically,
low COMT activity results in higher DA levels in the prefrontal cortex (PFC), thereby reducing the vulnerability
for attentional and cognitive deficits in both psychotic and healthy individuals. COMT activity is markedly
reduced by a non-synonymous single-nucleotide polymorphism (SNP) that generates a valine-to-methionine
substitution on the residue 108/158, by means of as-yet incompletely understood post-translational mechanisms.
One post-translational modification is methionine sulfoxide, which can be reduced by the methionine sulfoxide
reductase (Msr) A and B enzymes. We used recombinant COMT proteins (Val/Met108) and mice (wild-type (WT)
and MsrA knockout) to determine the effect of methionine oxidation on COMT activity and COMT interaction
with Msr, through a combination of enzymatic activity and Western blot assays. Recombinant COMT activity is
positively regulated by MsrA, especially under oxidative conditions, whereas brains of MsrA knockout mice
exhibited lower COMT activity (as compared with their WT counterparts). These results suggest that COMT ac-
tivity may be reduced by methionine oxidation, and point to Msr as a key molecular determinant for the modu-
lation of COMT activity in the brain. The role of Msr in modulating cognitive functions in healthy individuals
and schizophrenia patients is yet to be determined.
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Introduction
The enzyme catechol-O-methyltransferase (COMT) cata-
lyzes the O-methylation of catecholamine neurotransmit-
ters, such as dopamine (DA) and norepinephrine
(Axelrod and Tomchick, 1958), using S-adenosylmethio-
nine (SAM) as a methyl donor (Männistö and Kaakkola,
1999). The COMT protein occurs as two distinct isoforms
with identical kinetic mechanisms, which result from dif-
ferential transcriptions of the corresponding gene: a sol-
uble form (S-COMT), found in the cell cytoplasm; and
a membrane-bound form (MB-COMT), which features
50 additional residues in the N-terminal portion of
the protein (Huh and Friedhoff, 1979; Männistö and
Kaakkola, 1999).
Several lines of evidence have shown that COMT
serves a primary role in DA degradation in the prefrontal
cortex (PFC) (Karoum et al., 1994; Matsumoto et al.,
2003a,b). Given the well-documented implication of
DAergic neurotransmission in the modulation of these
tasks (Miller and Cohen, 2001; Cohen et al., 2002;
Nieoullon, 2002), the functional role of COMT in the
PFC has garnered substantial interest. In particular, nu-
merous investigations have focused on rs4680, one of
the best-characterized single-nucleotide polymorphisms
(SNPs) of the COMT gene, resulting in the substitution
of a valine (Val) for a methionine (Met) residue at position
108 of S-COMT and 158 of MB-COMT (Val108/158Met)
(Lachman et al., 1996). The Met allele is associated with
reduced COMT activity and lower DA metabolism; this
functional characteristic has been shown to lead to a
more efficient physiological response in the PFC across
several functional domains, including cognitive flexibil-
ity, working memory, attentional control and emotional
resilience (Malhotra et al., 2002; Goldberg et al., 2003;
Blasi et al., 2005; Smolka et al., 2005).
The notion that low DAergic activity in the PFC
may contribute to negative and cognitive symptoms of
schizophrenia patients (Davis et al., 1991; Kahn and
Davis, 1995), has also led several authors to investigate
the potential influence of the rs4680 polymorphism of
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COMT on the severity of these deficits in psychotic disor-
ders. Multiple studies have ascertained that the Met108/158
variant is associated with a slightly lower schizophrenia
risk, as well as less severity of attentional, cognitive
and information-processing deficits (Egan et al., 2001;
Bilder et al., 2002; Bray et al., 2003; Gallinat et al., 2003;
Tunbridge et al., 2006; Ehlis et al., 2007).
Previous research has shown that the Val108/158Met
genotype affects protein expression, but not messenger
RNA (mRNA) expression levels, indicating that this poly-
morphism may lead to post-translational changes in the
protein (Matsumoto et al., 2003a,b; Chen et al., 2004).
Indeed, it has been shown that the methionine-to-valine
substitution reduces the thermostability of the enzyme
without affecting its structural and kinetic properties
(Lotta et al., 1995; Lachman et al., 1996). Although the
bases of this phenomenon are not fully elucidated, the
lower catalytic activity of the Met108/158 variant has been
associated with a markedly higher susceptibility to oxi-
dation (Cotton et al., 2004). The most oxidation-sensitive
amino acids are the sulfur-containing methionine and
cysteine. Indeed, Cotton and co-workers (Cotton et al.,
2004) identified a key role of cysteine residues in the vul-
nerability of the Met108/185 variant to oxidation; the
specific role of methionine in this process, however, re-
mains elusive. The oxidation of methionine residues
leads to the formation of methionine sulfoxide (MetO);
this well-known phenomenon is enhanced by oxidative
stress and reversed by the methionine sulfoxide
reductase (Msr) system, consisting of two enzymes
(termed A and B) that reduce either S or R enantiomers
of MetO, respectively (Moskovitz et al., 2000, 2002;
Moskovitz, 2005).
In this study, we hypothesized that the lower catalytic
activity of the Met108/158 variant may be also contributed
by the oxidation of this and other methionine residues.
To test for this possibility, we assessed whether COMT
activity may be affected by Msr, using a number of comp-
lementary in vitro and ex vivo approaches.
Methods
Recombinant human COMT and MsrA proteins
Expression clones for recombinant His-tag soluble
human COMT proteins (S-COMT, Val108 and Met108
forms) were kindly provided by Dr Klinman (University
of California, USA). The expression and purification
of the recombinant COMT proteins were performed as
described by Zhang and Klinman (2011). Recombinant
His-tagged yeast MsrA protein was expressed and
purified as previously described (Moskovitz et al.,
1997). Oxidation of recombinant COMT proteins was
performed by incubating the proteins with 200mM
H2O2 for 24 h at room temperature. Then, the residual
H2O2 was removed by dialysis against 25mM Tris-HCl
(pH 7.4) at 4 °C.
Animals
Wild type (WT) and MsrA knockout (KO) mice
(n=10/group) were obtained as previously reported
(Moskovitz et al., 2001). Animals were housed in group
cages with ad libitum access to food and water. The room
was maintained at 22 °C, on a 12 h: 12 h light/dark cycle.
Experimental procedures were in compliance with the
accepted National Institute of Health guidelines (such
as ‘Guiding principles in the care and use of animals’
(DHEW Publications, NIH, 80-23) and approved by the
Animal Use Committees of the University of Kansas.
Quantification of COMT levels in brains of WT and
MsrA KO mice
Mice were euthanized at 6 and 12 months of age, by CO2
asphyxiation followed by cervical dislocation (n=5 per































































Fig. 1. Effects of dithiothreitol (DTT) and methionine sulfoxide
reductase (Msr) A on the activities of catechol-O-methyl
transferase (COMT) Val108 and Met108 variants in vitro under
(a) standard conditions and (b) high H2O2 concentrations.
Values are displayed as means±S.E.M. All analyses were run by
two-way analysis of variance (ANOVA), followed by
Newman–Keuls test for post-hoc comparisons. ***, p<0.001 for
comparisons vs. corresponding Val108 (genotype× treatment
interaction); °°°, p<0.001 for comparison vs. 2mM DTT (main
treatment effect); ^^^, p<0.01 for comparison vs. 20mM DTT
(main treatment effect). Main genotype effects are not shown.
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euthanasia and frozen on dry ice. The tissues were stored
in −80 °C until use. Tissues were homogenized using a
Teflon homogenizer in the presence of 25mM Tris-HCl
(pH 7.4) and protease inhibitors cocktail (Roche Applied
Science, USA) at 4 °C. Following centrifugation at
10000 g for 20min, the supernatants were collected and
their protein concentrations were assessed using a
Bio-Rad (USA) assay kit. Equal protein amounts were
subjected to SDS-gel electrophoresis followed by western
blot analyses using anti-COMT mouse antibodies (BD
Biosciences, USA) as the primary antibodies. Horseradish
peroxidase (HRP)-conjugated goat anti-mouse antibodies
(Santa Cruz Biotechnology, USA) were used as the
secondary antibodies. Anti-ß-actin mouse antibodies
(Abcam, USA) were also used on the same blot as pri-
mary antibodies (after stripping the blot) for the assess-
ment of protein loading control. Following exposure
of the blot to an X-ray film, the resulting protein band
images were quantified using the Image-J program
(National Institute of Health, USA).
COMT mRNA levels in brains of both mouse geno-
types were determined by real-time polymerase chain
reaction (RT-PCR) (using primers 1418701 and 144918,
Affymetrix, USA).
Statistical analyses
Normality and homoscedasticity of data distribution
were verified by using Kolmogorov–Smirnov and
Bartlett’s tests. Non-parametric data were normalized
by logarithmic transformation. Statistical analyses were
performed using analysis of variance (ANOVA), fol-
lowed by Newman–Keuls test for post-hoc comparisons.
Significance threshold was set at 0.05. All statistical analy-
ses were performed by STATISTICA 7 (Statsoft, USA).
Results
Effect of MetO reduction on recombinant COMT
activity
To determine the combined effect of the rs4680 poly-
morphism and methionine oxidation on S-COMT activity,
we monitored the activity of purified His-tagged human
recombinant COMT of Val108 (native) and Met108 forms.
First, we analyzed the activity of the recombinant
enzymes in the presence of 2mM dithiothreitol (DTT),
a reducing agent that maintains cysteine residues in
their reduced form (Fig. 1a). Under these conditions, the-
mean activity (±S.E.M) of the Met108 COMT variant was
69±7.72% of the native form (p<0.001) (Fig. 1a).
Increasing the DTT concentration to 20mM caused a sig-
nificant increase in the activity of both COMT forms
(p<0.001) (Fig. 1a), without affecting the activity gap
between them (Fig. 1a). The addition of recombinant
MsrA in the presence of 20mM DTT further increased
the activities of both forms of S-COMT (p<0.05), and
ablated their difference in catalytic activity (Fig. 1a), sug-
gesting that COMT activity is negatively affected by
methionine oxidation in vitro, especially in the Met108
form. To further elucidate the possible negative effect of
oxidizing COMT methionine residues (including Met108)
on enzyme activity, both versions of the recombinant
S-COMT were exposed to high concentrations of H2O2
prior to monitoring COMT activity. As shown in
Fig. 1b, COMT activity was reduced in the Met108 variant
in comparison to the Val108 variant, similar to the levels
observed under non-oxidizing conditions, in the presence
of DTT only. However, although the addition of recombi-
nant MsrA caused significant increases in the activities of
both COMT variants (p<0.001) (Fig. 1b), there was a sign-
ificant gap between the two COMT variants. These data
suggest that, under severe oxidative conditions in vitro,
Table 1. Protein sequence homology alignment between mouse and human catechol-O-methyl transferase (COMT). Met (M) residues
are in bold and 158 Val of the human COMT is both in bold and underlined
Mouse 20 RHLGWGLVAIGWFEFVQQPVHNLLMGGTKEQRILRHVQQHAKPGDPQSVLEAIDTYCSEK 79
RH GWGL IGW EF+QP+HNLLMG TKEQRIL HV QHA+PG+QSVLEAIDTYC+K
Human 27 RHWGWGLCLIGWNEFILQPIHNLLMGDTKEQRILNHVLQHAEPGNAQSVLEAIDTYCEQK 86
Mouse 80 EWAMNVGDAKGQIMDAVIREYRPSLVLELGAYCGYSAVRMARLLPPGARLLTMEINPDYA 139
EWAMNVGD KG+I+DAVI+E++PS++LELGAYCGYSAVRMARLL PGARL+T+EINPD A
Human 87 EWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCGYSAVRMARLLSPGARLITIEINPDCA 146
Mouse 140 AITQQMLDFAGLQDKVSILIGASQDLIPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEE 199
AITQ+M+DFAG++DKV++++GASQD+IPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEE
Human 147 AITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEE 206
Mouse 200 CGLLRKGTVLLADNVIVPGTPDFLAYVRGSSSFECTHYSSYLEYMKVVDGLEKAVYQGPG 259
CGLLRKGTVLLADNVI PG PDFLA+VRGSS FECTHY S+LEY+VVDGLEKA+Y+GPG
Human 207 CGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFECTHYQSFLEYREVVDGLEKAIYKGPG 266
Mouse 260 SS 261
S
Human 267 SE 268
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the difference in activity between Val108 and Met108 forms
is not fully rescued.
Genetic ablation of MsrA leads to significant reduction
of COMT activity in the mouse brain
To test the relevance in vivo of the relation between MsrA
and COMT, we measured the activity of the latter enzyme
in the brains of MsrA KO mice, as compared with WT
counterparts. The primary sequences of murine and
human COMT share sequence homology for 5 methion-
ine residues. The mouse protein contains additional
methionine residues at positions 93 and 244 (Table 1),
and features a leucine residue (a hydrophobic amino
acid such as valine and methionine) in the position 151,
homolog to 108/158 in human COMT (Table 1).
The brains of MsrA KO mice exhibited a marked re-
duction in COMT activity [Main genotype effect:
F(1,24)=175.05, p<0.001] (Fig. 2a). The increase of DTT
concentration to 20mM produced a significant enhance-
ment in COMT activity in both WT and KO mice (173
and 132% in comparison to WT and MsrA KO treated
with 2mM DTT, respectively; Main treatment effect:
F(1,24)=105.46, p<0.001 in comparison with 2mM DTT).
Finally, the addition of recombinant MsrA protein to
the assay reaction (in the presence of 20mM DTT) further
significantly increased COMT activity across both geno-
types (Ps<0.001 compared with both 2 and 20mM DTT
(Fig. 2a). Notably, ANOVA failed to identify a significant
genotype× treatment interaction, indicating that the treat-
ment with DTT and MsrA did not abrogate the difference
between genotypes.
We then analyzed whether the differences in COMT
activity between WT and MsrA KO brains may be
influenced by aging (Fig. 2b). Although ANOVA found
significant main effects for genotype [F(1,16)=47.40,
p<0.001] and age [F(1,16)=32.64, p<0.001], no significant
interaction between these two effects was found, indicat-
ing that the age-dependent decline in COMT activity was
not dependent on MsrA genotype.
To confirm that the observed difference in COMT
activity between the two mouse genotypes is not attribu-
table to a difference in COMT mRNA protein expression
levels, COMT protein and mRNA levels were determined
in brains of both WT and MsrA KO mice. Accordingly,
western blot analysis and real-time PCR determination
of COMT’s mRNA levels were performed. As shown in
Fig. 3, the protein levels of COMT were equivalent across
both mouse genotypes. Complementary to these data,
there was no significant difference in the mRNA levels be-
tween the two mouse genotypes (data not shown).
Discussion
The findings of this study converge in support of a regu-
latory role of Msr on COMT activity in the brain, and,






























































Fig. 2. (a) Effects of dithiothreitol (DTT) and MsrA on the
brain activity of catechol-O-methyl transferase (COMT) in WT
and MsrA knockout (KO) mice, and (b) effects of aging on
COMT activity in wild-type (WT) and MsrA KO mice. Values
are displayed as means±S.E.M. All analyses were run by
two-way analysis of variance (ANOVA), followed by
Newman–Keuls test for post-hoc comparisons. ###, p<0.001 for
comparisons vs. corresponding WT group (main genotype
effect); °°°, p<0.001 for comparison vs. 2mM DTT (main
treatment effect); ^^^, p<0.01 for comparison vs. 20mM DTT
(main treatment effect); $$$, p<0.001 for comparison vs.





Fig. 3. Representative blots from Western blot analyses (n=5)
showing catechol-O-methyl transferase (COMT) expression in
comparison with β-actin expression in brain samples from
wild-type (WT) and MsrA knockout (KO) mice.
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countered the reduction of COMT activity induced by
oxidation; this effect was not only limited to the Met108
variant, but targeted also other methionine residues,
as suggested by the ability of MsrA to enhance the cata-
lytic activity of the Val108 variant (Fig. 1). In addition,
we found that in the mouse brain, COMT activity was
reduced by genetic MsrA deficiency and increased by ad-
dition of recombinant MsrA; nevertheless, the latter inter-
vention did not fully rescue the deficits of COMT activity
in MsrA KO mice. This phenomenon suggests that in
these mutants, COMT may feature post-translational
modifications that may interfere with the reduction of
R-MetO residues (Fig. 2). Supportive evidence for the
involvement of post-translational modifications to the
observed reduced COMT activity in MsrA KO mice arises
from the similar expression levels of COMT’s mRNA (data
not shown) and protein (Fig. 3) in both mouse strains.
These results suggest that COMT activity may be
reduced by the oxidation of its methionine residues,
and complements previous evidence documenting the
implication of cysteine (the other sulfur-containing
amino acid) in the higher susceptibility of the Met108/158
variant to oxidation (Cotton et al., 2004). Previous
data have shown that methionine oxidation causes con-
formational changes (Berlett et al., 1996) and increases
the hydrophobicity of proteins (Chao et al., 1997).
Interestingly, the increase in hydrophobicity owing to
MetO formation has also been shown to enhance the pro-
teolytic susceptibility of proteins (Levine et al., 1996),
suggesting that the Met108/158 variant may be more vul-
nerable to protease-mediated degradation. Accordingly,
theMet108/158 variant exhibits 20% of its activity at physio-
logical temperature; this phenomenon may be attribu-
table to the observed reduction in the protein
expression level (possibly because of its enhanced degra-
dation rate), but not mRNA expression level in brain
tissue (Lotta et al., 1995; Matsumoto et al., 2003a,b;
Chen et al., 2004). The robust association between Msr
and COMT is particularly noteworthy, in view of the pri-
mary role of COMT in the regulation of DA homeostasis
in the PFC (Gogos et al., 1998; Matsumoto et al., 2003a,b).
High COMT activity, such as that associated with the
Val108/158 variant, leads to increased DA turnover, which
may result in a higher predisposition for a number of
information-processing, attentional, executive and cogni-
tive deficits in patients with psychosis, as well as healthy
individuals (Kahn and Davis, 1995; Weinberger et al.,
2001; Weinberger, 2002; Barnett et al., 2007; Ira et al.,
2013). Furthermore, it should be noted that alterations
in oxidative stress in the PFC have been associated with
multiple psychiatric disorders, including schizophrenia,
bipolar disorder and major depression (Michel et al.,
2007; Gawryluk et al., 2011; Andreazza et al., 2013), as
well as cognitive and motivational deficits in mouse mod-
els (Johnson et al., 2013). These premises highlight the po-
tential importance of Msr as a moderator of COMT
function with respect to these functional domains
regulated by the PFC. Future studies are needed to test
this interesting hypothesis.
Previous studies have shown that MsrA KO mice exhi-
bit high levels of DA in the brain (and, particularly, in the
striatum), raising the possibility that the reduction in
COMT activity may be partially responsible for such
changes. Nevertheless, the contribution of COMT is un-
likely to fully account for the enhancement of DA levels
in MsrA KO mice; indeed, COMT KO mice only featured
increases in DA in the PFC, but not in the striatum (Gogos
et al., 1998).
One of the main limitations of this study is that our
observations were based on S-COMT, which is posited
to play a relatively less important role in DA degradation
in comparison with MB-COMT. Even with this limitation,
the identification of a link between Msr and COMT ac-
tivity points to the potential importance of methionine
oxidation in the modulation of prefrontal activity and
the pathophysiology of cognitive impairments of schizo-
phrenia. Future clinical studies are warranted to test the
implication of Msr in the function of COMT, particularly
with respect to the regulation of dopamine neurotrans-
mission and pathophysiology of schizophrenia.
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